Anthrax Clinical Trial
Official title:
Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults
The purpose of this Phase 3 clinical trial is to evaluate the immunogenicity and safety of BioThrax anthrax vaccine in healthy adults following 3 doses of BioThrax. Results of this study will be used to support a post-exposure prophylaxis (PEP) indication for BioThrax. This study will be conducted in the United States (U.S.), in 200 healthy male and female volunteer subjects ages 18 to 65 years. The duration of study participation for each individual subject will be approximately 128 days (4.25 months), including a screening period of approximately 28 days followed by 100 days on study.
BioThrax® (also called Anthrax Vaccine Adsorbed or AVA) is the only FDA-licensed vaccine for the prevention of anthrax infection. This study will evaluate the immunogenicity of the vaccine using a post-exposure vaccination schedule. Correlations will be drawn to immunogenicity and survival data from animal models to demonstrate that BioThrax® can elicit a protective immune response for PEP. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00114621 -
Anthrax Vaccine Clinical Trials
|
Phase 1 | |
| Recruiting |
NCT00050310 -
Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients
|
||
| Completed |
NCT01453907 -
Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult Volunteers
|
Phase 1 | |
| Completed |
NCT03518125 -
BARDA Securing Anthrax Immunity For the Elderly
|
Phase 2 | |
| Completed |
NCT04660201 -
Anthrax AV7909 Liquid vs Lyophilized
|
Phase 1 | |
| Completed |
NCT04320485 -
Evaluation of the Clinical Specificity of the Active Anthrax Detect™ Plus (AAD Plus) Lateral Flow Immunoassay (LFI)
|
||
| Recruiting |
NCT06365073 -
A Case-control Study on the Clinical Characteristics of 28-day and 90-day Death From Severe Anthrax
|
||
| Completed |
NCT03877926 -
VELOCITY: An Anthrax Vaccine Clinical Study
|
Phase 3 | |
| Completed |
NCT03498027 -
Febrile Whole Blood Specimen Collection and Testing
|
||
| Terminated |
NCT00964834 -
Ph1 Study of Valortim and Doxycycline in Humans
|
Phase 1 | |
| Completed |
NCT00063843 -
Anthrax-rPA: Safety, Tolerability, Immunogenicity
|
Phase 1 | |
| Completed |
NCT01624532 -
A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109
|
Phase 2 | |
| Completed |
NCT04148118 -
A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults
|
Phase 1 | |
| Terminated |
NCT05672875 -
Evaluation of the SRI B. Anthracis Lethal Factor Diagnostic System
|
||
| Completed |
NCT01770743 -
A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels
|
Phase 2 | |
| Completed |
NCT01867957 -
Efficacy and Safety of Anthrax Vaccine, GC1109
|
Phase 1 | |
| Completed |
NCT00845650 -
Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)
|
Phase 1/Phase 2 | |
| Completed |
NCT00031291 -
Plasmapheresis of Anthrax-Vaccinated Subjects for Production of Anthrax Immune Globulin
|
N/A | |
| Not yet recruiting |
NCT03569514 -
Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax
|
||
| Recruiting |
NCT05997264 -
Anthrax AV7909 Boost Evaluation Study
|
Phase 2 |